



# THE JOURNAL OF CLINICAL PSYCHIATRY

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

## Supplementary Material

**Article Title:** Symptomatic and Functional Response and Remission From the Open-Label Treatment-Optimization Phase of a Study With DR/ER-MPH in Children With ADHD

**Author(s):** Ann C. Childress, MD; Andrew J. Cutler, MD; Michelle D. Po, PhD;  
Norberto J. DeSousa, MA; Lewis E. Warrington, MD; Floyd R. Sallee, MD, PhD  
and Bev Incedon, PhD

**DOI Number:** <https://doi.org/10.4088/JCP.21m13914>

### List of Supplementary Material for the article

1. [Table 1](#) Symptom and Functional Impairment Assessments and Thresholds
2. [Figure 1](#) ADHD-RS-IV and BSFQ Scores with DR/ER-MPH Treatment

### Disclaimer


This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

**Supplementary Table 1. Symptom and Functional Impairment Assessments and Thresholds**

	Early Morning Functional Impairment				Symptoms				Late Afternoon/Evening Functional Impairment							
	BSFQ		PREMB-R AM		ADHD-RS-IV		PREMB-R PM									
Scale description	Validated 20-item clinician-rated scale based on a structured parent interview assessing early morning functional impairment between the time of awakening and getting to school or other morning activities (ie, from 6:00 AM to 9:00 AM) in children with ADHD. <sup>32</sup>				Validated 3-item clinician-rated subscale based on structured parent interview assessing functional impairment during the early morning (eg, getting up and out of bed). <sup>33,34</sup>				Validated 18-item clinician-rated scale evaluating ADHD symptomology based on the DSM-IV diagnostic criteria for ADHD. <sup>35</sup>				Validated 8-item clinician-rated subscale based on structured parent interview assessing functional impairment during the late afternoon/evening (eg, doing/completing homework, getting to bed, and falling asleep). <sup>34</sup>			
Scale scoring	Items rated from 0 (none) to 3 (severe); total scores range from 0 to 60. Scores reflected functional impairment over the preceding week. <sup>32</sup>				Items rated from 0 (none) to 3 (a lot); total scores range from 0 to 9. Scores reflected the last two school days prior to the study visit. <sup>33,34</sup>				Items rated from 0 (no symptoms) to 3 (severe symptoms); total scores range from 0 to 54. Scores reflected symptoms over the preceding week. <sup>35</sup>				Items rated from 0 (none) to 3 (a lot); total scores range from 0 to 24. Scores reflected the last two school days prior to the study visit. <sup>34</sup>			
Schedule	Assessed at each open-label visit; ≥33% improvement from baseline was required for randomization.				Assessed at the beginning and end of the 6-week open-label phase as well as following one week of double-blind treatment, which was included as a secondary endpoint.				Assessed at each open-label visit; ≥33% improvement from baseline was required for randomization.				Assessed at the beginning and end of the 6-week open-label phase as well as following one week of double-blind treatment, which was included as a secondary endpoint.			
Response threshold (anchored to CGI-I of 1 or 2)	Change from baseline of ≥45%. <sup>29</sup>				Change from baseline of ≥49%. <sup>29</sup>				Change from baseline of ≥40%. <sup>25</sup>				Change from baseline of ≥29%. <sup>29</sup>			
Remission threshold (corresponding to less than screening risk)	≤24 for individuals 6–8 years of age and ≤21 for individuals 9–12 years of age. <sup>30</sup>				≤4 for individuals 6–8 years of age and ≤3 for individuals 9–12 years of age. <sup>30</sup>				Score ≤18. <sup>13</sup>				≤10 for individuals 6–8 years of age and ≤8 for individuals 9–12 years of age. <sup>30</sup>			
Cut-offs for severity thresholds of temporal functional impairment <sup>30</sup>	SR	Mild	Mod	Sev	SR	Mild	Mod	Sev		SR	Mild	Mod	Sev			
	80 <sup>th</sup>	90 <sup>th</sup>	93 <sup>rd</sup>	98 <sup>th</sup>	80 <sup>th</sup>	90 <sup>th</sup>	93 <sup>rd</sup>	98 <sup>th</sup>		80 <sup>th</sup>	90 <sup>th</sup>	93 <sup>rd</sup>	98 <sup>th</sup>			
6–8 years	25	33	36	43	5	6	6	8		11	15	16	19			
9–11 years	22	30	36	43	4	6	6	8		9	13	16	19			
12–14 years	22	30	34	42	4	6	6	7		9	13	15	18			
15–17 years	21	28	31	42	4	6	6	7		9	13	15	18			

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; ADHD-RS-IV, ADHD Rating Scale-IV; BSFQ, Before School Functioning Questionnaire; CGI-I, Clinical Global Impressions-Improvement; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4<sup>th</sup> Edition; Mod, moderate; PREMB-R AM, Parent Rating of Evening and Morning Behavior, Revised, Morning subscale; PREMB-R PM, Parent Rating of Evening and Morning Behavior, Revised, Evening subscale; Sev, severe; SR, screening risk.

### Supplementary Figure 1. ADHD-RS-IV and BSFQ Scores with DR/ER-MPH Treatment



Note: Scores reflect symptoms and functional impairment over the preceding week. Therefore, baseline scores reflect the previous untreated week.

Abbreviations: ADHD-RS-IV, ADHD Rating Scale-IV; BSFQ, Before School Functioning Questionnaire; DR/ER-MPH, delayed-release and extended-release methylphenidate; SD, standard deviation.